NCT06120166View on ClinicalTrials.gov

Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical Research

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

November 16, 2023

Primary Completion Date

December 1, 2025

Study Completion Date

April 5, 2026

Conditions
Diffuse Large B-cell Lymphoma
Interventions
DRUG

Metabolically Armed CD19 CAR-T cells

Each subject receive metabolically armed CD19 CAR-T cells by intravenous infusion

Trial Locations (1)

310000

RECRUITING

The first affiliated hospital of medical college of zhejiang university, Hangzhou

Sponsors

Collaborators (1)

Leman Biotech Co., Ltd.
All Listed Sponsors
collaborator

Leman Biotech Co., Ltd.

INDUSTRY

lead

He Huang

OTHER